English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/151223
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Exportar a otros formatos:

DC FieldValueLanguage
dc.contributor.authorNaranjo, José Ramón-
dc.contributor.authorVillar, Diego-
dc.contributor.authorGonzález Pérez, Paz-
dc.contributor.authorDopazo, Xose M.-
dc.contributor.authorMorón-Oset, Javier-
dc.contributor.authorHigueras, Elena-
dc.contributor.authorOliveros, Juan C.-
dc.contributor.authorArrabal, María D.-
dc.contributor.authorPrieto, Ángela-
dc.contributor.authorCercós, Pilar-
dc.contributor.authorGonzález, Teresa-
dc.contributor.authorCruz, Alicia de la-
dc.contributor.authorCasado-Vela, Juan-
dc.contributor.authorRábano, Alberto-
dc.contributor.authorValenzuela, Carmen-
dc.contributor.authorGutiérrez-Rodríguez, Marta-
dc.contributor.authorMellström, Britt-
dc.identifierdoi: 10.1172/JCI82670-
dc.identifiere-issn: 1558-8238-
dc.identifierissn: 0021-9738-
dc.identifier.citationJournal of Clinical Investigation 126(2): 627-638 (2016)-
dc.description.abstractDeregulated protein and Ca2+ homeostasis underlie synaptic dysfunction and neurodegeneration in Huntington disease (HD); however, the factors that disrupt homeostasis are not fully understood. Here, we determined that expression of downstream regulatory element antagonist modulator (DREAM), a multifunctional Ca2+-binding protein, is reduced in murine in vivo and in vitro HD models and in HD patients. DREAM downregulation was observed early after birth and was associated with endogenous neuroprotection. In the R6/2 mouse HD model, induced DREAM haplodeficiency or blockade of DREAM activity by chronic administration of the drug repaglinide delayed onset of motor dysfunction, reduced striatal atrophy, and prolonged life span. DREAM-related neuroprotection was linked to an interaction between DREAM and the unfolded protein response (UPR) sensor activating transcription factor 6 (ATF6). Repaglinide blocked this interaction and enhanced ATF6 processing and nuclear accumulation of transcriptionally active ATF6, improving prosurvival UPR function in striatal neurons. Together, our results identify a role for DREAM silencing in the activation of ATF6 signaling, which promotes early neuroprotection in HD.-
dc.description.sponsorshipA. De la Cruz holds a RECAVA contract, A. Prieto and P. Cercós hold FPI fellowships, and T. González holds a Ramón y Cajal contract. J. Casado-Vela holds a JAE-DOC (CSIC) from the Spanish Ministerio de Economía y Competitividad (MINECO), cofunded by the European Social Fund. This work was funded by the Instituto de Salud Carlos III/CIBERNED (to J.R. Naranjo, B. Mellström, and A. Rábano), FISS-RIC RD12/0042/0019 (to C. Valenzuela), Madrid regional government/Neurodegmodels (to J.R. Naranjo), MINECO grants SAF2010-21784 and SAF2014-53412-R (to J.R. Naranjo), SAF2012-32209 (to M. Gutierrez-Rodriguez), SAF2010-14916 and SAF2013-45800-R (to C. Valenzuela), and a grant from the Swedish Research Council (J.Y. Li).-
dc.publisherAmerican Society for Clinical Investigation-
dc.relation.isversionofPublisher's version-
dc.titleActivating transcription factor 6 derepression mediates neuroprotection in Huntington disease-
dc.description.versionPeer Reviewed-
dc.contributor.funderEuropean Commission-
dc.contributor.funderConsejo Superior de Investigaciones Científicas (España)-
dc.contributor.funderInstituto de Salud Carlos III-
dc.contributor.funderSwedish Research Council-
dc.contributor.funderMinisterio de Economía y Competitividad (España)-
dc.contributor.funderComunidad de Madrid-
Appears in Collections:(IIBM) Artículos
(CNB) Artículos
(IQM) Artículos
Files in This Item:
File Description SizeFormat 
Huntington.pdf1,88 MBAdobe PDFThumbnail
Show simple item record

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.